Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry professionals · Tuesday, April 16, 2024 · 704,177,839 Articles · 3+ Million Readers

Florida Cancer Specialists Expands Number of Locations Offering DigniCap® Scalp Cooling System

DigniCap® Can Help Reduce Hair Loss from Chemotherapy Treatments

/EIN News/ -- Fort Myers, Fla., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) is pleased to announce it is expanding the number of locations in its statewide network that are offering the DigniCap® Scalp Cooling System to minimize hair loss from certain cancer treatments. By early November, FCS clinics in Lake Mary, Stuart and Orlando (Orange Ave.) will all offer DigniCap® to patients. With these additional clinics, patients can now receive DigniCap® services in a total of 20 locations within the FCS network.

FCS Chief Procurement Officer Paul Chadwick said, “With every location we add we are excited to bring DigniCap® to more of our patients. With over 130 patients treated already, we are bringing DigniCap® online at more sites through the end of the year and we have plans to expand further in 2021.”

Initially cleared by the FDA in 2015, DigniCap® is a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy by providing continuous cooling of the scalp with high efficacy, safety and acceptable patient comfort. DigniCap® can be used by both men and women who are receiving chemotherapy to treat solid tumors, such as those associated with breast, prostate, ovarian, uterine, lung and other tissues.

FCS CEO Nathan H. Walcker said, “Florida Cancer Specialists was an early adopter of DigniCap® and FCS physicians report great satisfaction from patients using the system. Bringing the most advanced and innovative technologies to our patients is an essential part of our mission as a community oncology practice to provide world-class cancer care in a setting close to home.”

FCS medical oncologist Julia Cogburn, MD added, “Hair loss is a common side effect of many chemotherapy drugs and, emotionally, this can be very difficult for some patients to process. It’s not only about concerns for their appearance; for some patients, hair loss is a constant reminder of the very serious illness they are fighting. DigniCap® allows these patients to feel better about their treatment and makes it easier to maintain a positive attitude, which can result in better outcomes.”

###

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)

Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. Over the past 5 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, MD Anderson, and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies, and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians, and staff.

*Prior to approval

Attachment

Shelly Glenn
                    Florida Cancer Specialists
                    (770) 365.6168
                    SGlenn@FLCancer.com
                    
                    Michelle Robey
                    Florida Cancer Specialists
                    (813) 767-9398
                    Michelle.Robey@FLCancer.com
                    
Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release